levodopa has been researched along with exenatide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abuirmeileh, A; Biggs, CS; Harkavyi, A; Kingsbury, AE; Lever, R; Whitton, PS | 1 |
| Abuirmeileh, A; Bloom, SR; Harkavyi, A; Lever, R; Rampersaud, N; Tadross, JA; Whitton, PS | 1 |
| Davies, JS; Elabi, OF; Lane, EL | 1 |
3 other study(ies) available for levodopa and exenatide
| Article | Year |
|---|---|
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Drug Evaluation, Preclinical; Endotoxins; Exenatide; Glucagon-Like Peptide-1 Receptor; Levodopa; Locomotion; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Receptors, Glucagon; Substantia Nigra; Tyrosine 3-Monooxygenase; Venoms | 2008 |
Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Drug Synergism; Dyskinesias; Exenatide; Glucagon-Like Peptide 1; Levodopa; Lizards; Male; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Venoms | 2012 |
L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.
Topics: Animals; Cell Movement; Corpus Striatum; Dopaminergic Neurons; Drug Interactions; Embryo, Mammalian; Exenatide; Female; Gene Expression; Glucagon-Like Peptide-1 Receptor; Graft Survival; Insulin Resistance; Leukocytes; Levodopa; Liraglutide; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2021 |